$CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Healthcare
Sector
Biotechnology
Industry
Aoife Brennan BCh MMSc
CEO
17
Employees
$6.11
Current Price
$382.51M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $350,252.84 | 50,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $879,381.84 | 150,000 | ||
| 3 months | Buys | 1 | 1 | $24,888.50 | 7,111 | 1:35.33 |
| Sells | 1 | 4 | $879,381.84 | 150,000 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Thomas Stephen Basil Director | Sale | 16,313 | $7.01 | $114,288.88 | View Details |
| Feb 25, 2026 | Thomas Stephen Basil Director | Sale | 33,687 | $7.00 | $235,963.96 | View Details |
| Feb 13, 2026 | Thomas Stephen Basil Director | Sale | 10,000 | $5.81 | $58,141.00 | View Details |
| Feb 12, 2026 | Thomas Stephen Basil Director | Sale | 90,000 | $5.23 | $470,988.00 | View Details |
| Jan 5, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 7,111 | $3.50 | $24,888.50 | View Details |
4 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.19
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$HOWL โ Werewolf Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$PEPG โ PepGen Inc.via RA CAPITAL MANAGEMENT, L.P.$TYRA โ Tyra Biosciences, Inc.via RA CAPITAL MANAGEMENT, L.P.$MLYS โ Mineralys Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$BCAX โ Bicara Therapeutics Inc.via RA CAPITAL MANAGEMENT, L.P.